Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-09-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
独立董事对第五届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding decisions made at a board meeting, including appointments of senior management and approvals related to the use of idle funds. It references compliance with stock exchange listing rules and company bylaws. The content focuses on board/management matters and governance-related approvals rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (1204 characters) and does not contain financial statements or detailed financial data. Therefore, it is best classified as Board/Management Information (MANG).
2022-09-13 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司补充确认受让天津华普海河生物医药产业基金合伙企业（有限合伙）份额之关联交易事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding a related-party transaction involving Tianjin Ruipu Biotechnology Co., Ltd. It discusses the background, purpose, risks, and approvals related to the company's acquisition of shares in a private equity fund. The document includes references to regulatory compliance, board and shareholder approvals, and independent directors' opinions. It is not a financial report, earnings release, or announcement of voting results, but rather a formal audit or verification opinion on a specific transaction. The document length is 2535 characters, which is relatively short but contains substantive content related to the audit and verification of a related-party transaction. Therefore, it fits best under Audit Report / Information (AR). Q3 2022
2022-09-13 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司增加使用闲置自有资金购买理财产品额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from China Galaxy Securities regarding the increase in the limit for using idle proprietary funds to purchase wealth management products by Tianjin Ruipu Biotechnology Co., Ltd. It includes information about the board meeting approval, investment purpose, risk analysis, independent director opinions, supervisory board opinions, and the sponsor's verification opinion. The document is regulatory in nature, related to compliance with stock exchange rules and internal governance, but it does not contain financial statements or quarterly/yearly financial results. It is not an earnings release, annual report, or interim report. It is also not a proxy solicitation or voting result announcement. The document is a formal regulatory announcement about a financing-related operational decision and compliance verification. Given the content and length (2704 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-13 Chinese
第五届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the fifth board of directors of Tianjin Ruipu Biotechnology Co., Ltd. It details the election of the chairman, appointment of board committees, hiring of senior management, and approval of financial management proposals. The document includes voting results and references to related announcements on official stock exchange websites. There are no financial statements or detailed financial data presented, and the document focuses on board and management changes and decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2856 characters, which is consistent with an announcement rather than a full report.
2022-09-13 Chinese
关于增加使用闲置自有资金购买理财产品额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the increase in the limit for using idle funds to purchase financial products. It details the board resolutions, investment purpose, risk analysis, and approvals from independent directors and supervisory board. The document is a formal announcement of a corporate financing-related decision but does not contain financial statements or detailed financial results. It is not a full financial report, earnings release, or management discussion. The document is a corporate announcement about capital usage and investment limits, fitting the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it contains substantive information about the financing decision itself. Therefore, the best classification is CAP with high confidence.
2022-09-13 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司增加使用闲置募集资金进行现金管理额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding Tianjin Ruipu Biotechnology Co., Ltd.'s increase in the quota for using idle raised funds for cash management. It includes specifics about the raised funds, board approvals, independent director opinions, supervisory board opinions, and the sponsor's verification opinion. The document is focused on the use and management of raised funds, approvals, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to fundraising and fund usage, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update (CAP) or Audit Report (AR). The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2022-09-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.